VERTEX PHARMACEUTICALS INC / MA Q1 FY2025 earnings call

Key Points - Revenue: $2.77 billion in Q1 2025, 3% growth y-o-y. - New Product Launches: ALYFTREK (CF) and JOURNAVX (acute pain) launched in U.S. - CASGEVY: Global launch continuing, reaching more patients with gene-edited therapy for sickle cell and beta-thalassemia. - R&D Progress: 4 programs in pivotal development, 3 Phase III programs on track for interim analysis/enrollment this year. Alpine acquisition milestones: Povetacicept completed interim analysis cohort in IgAN trial and advanced to pivotal in membranous nephropathy. - CF: ALYFTREK expected EU approval in H2 2025, NG 3.0 CFTR regimen on track. - Pain: Suzetrigine in DPN study ongoing, VX-993 Phase II trial in acute pain to report results H2 2025. - Type 1 Diabetes: Zimislecel on track for regulatory submissions in 2026. - Kidney Programs: Pove in IgAN and membranous nephropathy, Inaxaplin in AMKD, VX-407 in ADPKD in Phase II.

Vertex Pharmaceuticals reported $2.77 billion in revenue for the first quarter of 2025, representing a 3% growth compared to Q1 2024. Key product segments: CF segment saw growth with the launch of ALYFTREK and continued global rollout of CASGEVY. Pain segment had the launch of JOURNAVX. Revenue from CASGEVY was $14 million in Q1. The CF portfolio continued to grow eligible patients on CFTR modulators, with regulatory progress enabling expansion to younger patients. ALYFTREK, the fifth CFTR modulator, had a strong U.S. launch with uptake from various patient groups.

Guidance - Raised 2025 total revenue guidance to $11.85 billion to $12 billion (midpoint 8% growth at current exchange rates), reflecting CF portfolio growth, CASGEVY ramp, and JOURNAVX revenue in H2 2025. - No change to 2025 combined R&D, Acquired IPR&D, and SG&A guidance of $4.9 billion to $5 billion, including ~$100 million IPR&D charges. - Immaterial tariff impact expected due to low China exposure and diverse supply chain. - Unchanged 2025 non-GAAP effective tax rate guidance of 20.5% to 21.5%.

Risks - Dynamic tariff situation with potential sector-specific tariffs, though current exposure is low. - Temporary pause in VX-522 study due to tolerability issue, affecting study integrity until more info is available.

Q: Feedback on utilizing sweat chloride as a biomarker for ALYFTREK and what's compelling about ALYFTREK's profile?

A: Stuart Arbuckle noted sweat chloride isn't routinely used in CF practice, but ALYFTREK's appeal is the combination of non-inferiority to TRIKAFTA on FEV1, improved CFTR function via sweat chloride, additional mutations covered, and once-daily dosing.

Q: Tariff impact on Vertex?

A: Charlie Wagner stated immaterial impact due to low China exposure and diverse supply chain, but outlook subject to tariff changes.

Q: Early adopters of ALYFTREK and JOURNAVX payer status?

A: Stuart Arbuckle said ALYFTREK uptake from naive patients, discontinued patients, and TRIKAFTA transitions. Duncan McKechnie discussed JOURNAVX payer progress with 94 million lives covered, 22 million via commercial PBM agreement.

Q: CASGEVY uptake hurdles?

A: Stuart Arbuckle cited establishing authorized treatment centers, securing access/reimbursement, and center familiarity with treatment process as key to CASGEVY uptake.

Q: VX-993 and JOURNAVX pain data?

A: Reshma Kewalramani said VX-993 Phase II trial in acute pain post bunionectomy to report results H2 2025. Duncan McKechnie discussed JOURNAVX momentum, including 25,000 prescriptions and broad payer coverage progress.

Q: VX-522 study pause?

A: Reshma Kewalramani stated team is assessing tolerability issue, will update when more info available.

Q: ALYFTREK launch comparison to past CF launches?

A: Stuart Arbuckle said ALYFTREK's launch is different due to additional mutations covered and patient groups, but early uptake positive and expected to continue.